Toripalimab with Fruquintinib as the third-line treatment for refractory advanced metastatic colorectal cancer: Results of a single-arm, single-center, prospective, phase II clinical study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback